BCM857

BCM857 is a small molecule agonist of the Trace Amine-Associated Receptor 1 (TAAR1) being developed by Shanghai Yunsheng Yanxin Biotechnology for the treatment of schizophrenia. As a TAAR1 agonist, it represents a novel, non-dopamine D2 receptor-binding approach to antipsychotic therapy. By activating TAAR1, an intracellular G protein-coupled receptor, the drug modulates the activity of dopaminergic, serotonergic, and glutamatergic systems. This mechanism is intended to provide antipsychotic efficacy while potentially avoiding the common side effects associated with traditional D2 antagonists, such as extrapyramidal symptoms, weight gain, and prolactin elevation. BCM857 is currently in early-stage clinical development, with Phase 1 trials evaluating its safety, tolerability, and pharmacokinetics.